CAWM
SNDX icon

Capital A Wealth Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Capital A Wealth Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30
Closed -$369 – 769
2025
Q1 		$369 Hold
30
– – ﹤0.01% 650
2024
Q4 		$397 Buy
+30
New +$513 ﹤0.01% 680

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Capital A Wealth Management's SNDX Position: Q2 2025 in Review

Capital A Wealth Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2025, closing a stake of 30 shares — an estimated $369 sold.

Capital A Wealth Management first reported a position in SNDX in Q4 2024 and held it in 2 quarters. The position peaked at $397 in Q4 2024. 216 funds tracked by Wall St. Rank hold SNDX as of Q2 2025.

  • Capital A Wealth Management reported no remaining Syndax Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Capital A Wealth Management sold 30 Syndax Pharmaceuticals shares in Q2 2025, an estimated $369.
  • Capital A Wealth Management first reported a position in Syndax Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Capital A Wealth Management's Syndax Pharmaceuticals position peaked at $397 in Q4 2024.
  • 216 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2025.

Based on Capital A Wealth Management's 13F filing for Q2 2025, filed 26 Sep 2025.